| abstract |
1. A fast-melt oral composition comprising: (a) valdecoxib in particulate form in a therapeutically effective amount, (b) at least one pharmaceutically acceptable solution retarder, and (c) at least one pharmaceutically acceptable excipient which It has a rapid oral dissolution; the composition being organoleptically acceptable. 2. The composition of claim 1 which, when subjected to the in vitro No. 701 disintegration test of the United States Pharmacopoeia 24, has a shorter disintegration time of approximately 300 seconds. 3. The composition of claim 1 which disintegrates in approximately 60 seconds after being placed in the oral cavity of a human subject. 4. The composition of claim 1, wherein the "at least one "Pharmaceutically acceptable solution retarder" is a polymer. 5. The composition of claim 4, wherein the polymer is present in a total amount of approximately 0.5% to about 15% by weight. 6. The composition of claim 1, wherein the "at least one pharmaceutically acceptable solution retarder" is selected from the group consisting of ethyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, Eudragit® EP O and equivalent products of polymethacrylate, hydroxypropylethylcellulose and hydroxypropylcellulose.7.- The composition of claim 1, wherein the "at least one pharmaceutically acceptable solution retarder" is Eudragit® EP O or an equivalent polymethacrylate product .8.- The composition of claim 1, wherein the "at least one pharmaceutically acceptable excipient having a rapid oral solution" is a carbohydrate. |